All News

Help female patients stay informed about prevention strategies, symptoms, and treatment of this potentially deadly condition.

Continuous glucose monitors were associated with a decline in levels of HbA1c as well as reduced emergency department visits and hospitalizations for hypoglycemia.

After identifying 3 novel checkpoints involved in immunosuppression and autoimmune diseases, investigators developed recombinant proteins that could be used in this patient population.

Susan Lang, MA, MBA, CEO of XIL Health and former senior executive at Express Scripts, discusses some of the issues pharmacies are experiencing around staffing to support COVID-19 immunizations and how these issues may change post-pandemic.

The Pharmacy Times® Pharmacy Focus podcast provides the latest industry news and information, thought-leader insights, clinical updates, patient counseling tools, and innovative solutions for the everyday practice and business of pharmacy.

Concerns surrounding the vaccination of this population stemmed from the effects that cancer and its treatments can have on the immune system, but the investigators said this study should alleviate those fears.

Studies suggest bipolar disorder is associated with increased potential for stroke and higher odds of experiencing poor outcomes.

Dupilumab is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins.

Investigators from Monash University determined the prevalence of undiagnosed type 2 diabetes utilizing machine learning to analyze modifiable markers not included in screening guidelines.

To recognize National PTSD Awareness Month in June, Pharmacy Times interviewed Jordan Tishler, MD, on how medical cannabis can be used to treat PTSD among veterans and the general public.

Teclistamab is an off-the-shelf, T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 receptors.

The collaborative effort by pharmacies, which include Walgreens, CVS, and Albertsons Company stores, is part of the National Month of Action for COVID-19 vaccinations.

Susan Lang, MA, MBA, CEO of XIL Health and former senior executive at Express Scripts, on some of the ways pharmacies have been affected by the COVID-19 pandemic over the past year.

Because health care is a constantly evolving field, research pharmacist Brian Wortz, PharmD, of Cancer Treatment Centers of America, said pharmacists must be aware of the newest findings and how they could impact their patients.

Pharmacy Times spoke to Dr. Douglas Scharre, neurologist and director of the division of Cognitive Neurology at Ohio State Wexner Medical Center, about the latest FDA approved drug for Alzheimer disease.

By encouraging patients to find activities they enjoy and celebrating small improvements, health care professionals can help patients improve mild to moderate hypertension and elevated cholesterol.

Pharmacists play a role in prevention of opioid overdose by providing information to patients about signs and symptoms.

Pharmacists and pharmacy technicians can more efficiently and proactively incorporate their expertise into patient care, reduce the administrative burden on nursing staff, and help patients overcome financial obstacles and other hurdles to accessing medications.

Risankizumab-rzaa (Skyrizi, AbbVie) is approved for the treatment of moderate-to-severe plaque psoriasis among adults who are candidates for systemic therapy or phototherapy.

Pharmacists can be instrumental in helping to curtail the prevalence of psychotropic medication misuse while also providing unique expertise on drug information.

Vast opportunities are opening every day for pharmacists, especially with the upcoming complex biological products that need a lot of therapeutic drug monitoring and fine adjustment of doses.

Jay Lieberman, MD, a pediatric infectious disease specialist and the senior medical director of PRA Health Sciences, discusses the value of the pharmacist in administering COVID-19 vaccines to adolescents and children.

Data were presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Conference.

Data from a phase 3 trial comparing acalabrutinib against ibrutinib in adults with previously treated CLL showed acalabrutinib presented with non-inferior PFS and significantly fewer events of atrial fibrillation.

The study also found significant variation in treatment of children and adolescents hospitalized with COVID-19.

In an interview with Pharmacy Times, Brian Wortz, PharmD, said he enjoys the innovation in his research, especially when their findings have the potential to drastically impact patients’ lives.

Phase 3 data presented at the 2021 ASCO Annual Meeting have reinforced the long-term survival benefits and well-established safety profile of single-agent ibrutinib for patients with CLL.

This reduction in white matter has been well-documented, but the exact mechanism of action has been unknown until now, according to the study authors.